Concepts (162)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neutrophils | 4 | 2025 | 145 | 1.080 |
Why?
|
| Granulocytes | 2 | 2023 | 26 | 1.000 |
Why?
|
| Boronic Acids | 3 | 2014 | 21 | 1.000 |
Why?
|
| Pyrazines | 3 | 2014 | 32 | 0.990 |
Why?
|
| Multiple Myeloma | 4 | 2014 | 48 | 0.860 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2014 | 307 | 0.740 |
Why?
|
| Lung | 4 | 2025 | 492 | 0.660 |
Why?
|
| Antineoplastic Agents | 6 | 2014 | 1019 | 0.620 |
Why?
|
| Deoxyribonuclease I | 3 | 2025 | 26 | 0.590 |
Why?
|
| HIV Infections | 2 | 2023 | 2586 | 0.570 |
Why?
|
| Neoplasm Metastasis | 2 | 2016 | 237 | 0.530 |
Why?
|
| Cell Line, Tumor | 7 | 2016 | 2676 | 0.480 |
Why?
|
| Apoptosis | 4 | 2014 | 1568 | 0.460 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2010 | 20 | 0.420 |
Why?
|
| NF-kappa B | 2 | 2014 | 358 | 0.400 |
Why?
|
| Nanoparticles | 3 | 2025 | 460 | 0.390 |
Why?
|
| Pyrimidines | 3 | 2010 | 139 | 0.380 |
Why?
|
| Interleukin-6 | 2 | 2013 | 165 | 0.360 |
Why?
|
| Piperazines | 3 | 2010 | 120 | 0.340 |
Why?
|
| Doxorubicin | 2 | 2012 | 97 | 0.330 |
Why?
|
| Blast Crisis | 1 | 2010 | 2 | 0.330 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2010 | 10 | 0.330 |
Why?
|
| Caveolin 1 | 1 | 2010 | 33 | 0.330 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2010 | 49 | 0.320 |
Why?
|
| Kidney Neoplasms | 1 | 2010 | 80 | 0.310 |
Why?
|
| Lung Neoplasms | 2 | 2016 | 495 | 0.300 |
Why?
|
| RNA Interference | 1 | 2010 | 247 | 0.300 |
Why?
|
| Quinazolines | 1 | 2008 | 38 | 0.280 |
Why?
|
| Mice | 8 | 2025 | 6644 | 0.280 |
Why?
|
| Cohort Studies | 2 | 2022 | 1759 | 0.280 |
Why?
|
| Curcumin | 1 | 2008 | 118 | 0.260 |
Why?
|
| Humans | 16 | 2025 | 43102 | 0.240 |
Why?
|
| Neutrophil Activation | 1 | 2025 | 10 | 0.230 |
Why?
|
| Lung Injury | 1 | 2025 | 18 | 0.230 |
Why?
|
| Pulmonary Fibrosis | 1 | 2025 | 38 | 0.230 |
Why?
|
| Lipids | 1 | 2025 | 256 | 0.200 |
Why?
|
| Mice, Inbred C57BL | 4 | 2025 | 1869 | 0.190 |
Why?
|
| Animals | 8 | 2025 | 16992 | 0.180 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2022 | 21 | 0.180 |
Why?
|
| Histones | 1 | 2023 | 197 | 0.180 |
Why?
|
| Fibrosis | 1 | 2022 | 169 | 0.180 |
Why?
|
| Actins | 1 | 2022 | 164 | 0.180 |
Why?
|
| Fibroblasts | 2 | 2022 | 281 | 0.170 |
Why?
|
| Inflammation | 2 | 2025 | 758 | 0.170 |
Why?
|
| Transplantation, Heterologous | 2 | 2010 | 98 | 0.160 |
Why?
|
| Mice, SCID | 2 | 2010 | 158 | 0.160 |
Why?
|
| Cell Lineage | 2 | 2019 | 104 | 0.160 |
Why?
|
| Phenotype | 1 | 2022 | 780 | 0.160 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2009 | 5 | 0.150 |
Why?
|
| Proteomics | 1 | 2022 | 378 | 0.150 |
Why?
|
| Drug Synergism | 3 | 2008 | 195 | 0.150 |
Why?
|
| Signal Transduction | 4 | 2014 | 2157 | 0.150 |
Why?
|
| Mesoderm | 1 | 2019 | 73 | 0.150 |
Why?
|
| Phosphorylation | 3 | 2013 | 986 | 0.140 |
Why?
|
| Adipocytes | 1 | 2019 | 60 | 0.140 |
Why?
|
| Gestational Age | 1 | 2019 | 200 | 0.140 |
Why?
|
| Aging | 1 | 2023 | 783 | 0.140 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 148 | 0.130 |
Why?
|
| Pregnancy | 2 | 2022 | 1772 | 0.130 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2019 | 300 | 0.130 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 665 | 0.120 |
Why?
|
| K562 Cells | 3 | 2010 | 32 | 0.120 |
Why?
|
| Cell Differentiation | 1 | 2019 | 638 | 0.120 |
Why?
|
| Female | 9 | 2025 | 24698 | 0.110 |
Why?
|
| Benzamides | 3 | 2010 | 81 | 0.110 |
Why?
|
| Mice, Inbred BALB C | 1 | 2016 | 694 | 0.110 |
Why?
|
| Cells, Cultured | 1 | 2019 | 1621 | 0.110 |
Why?
|
| Syndecan-1 | 1 | 2014 | 9 | 0.110 |
Why?
|
| Thalidomide | 1 | 2014 | 6 | 0.110 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 3156 | 0.100 |
Why?
|
| Cell Proliferation | 3 | 2009 | 1455 | 0.100 |
Why?
|
| Ubiquitination | 1 | 2014 | 62 | 0.100 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2012 | 51 | 0.100 |
Why?
|
| Janus Kinase 2 | 1 | 2013 | 36 | 0.100 |
Why?
|
| Cell Movement | 1 | 2016 | 655 | 0.090 |
Why?
|
| Disease Models, Animal | 2 | 2025 | 1596 | 0.090 |
Why?
|
| RNA, Small Interfering | 2 | 2013 | 436 | 0.090 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2012 | 69 | 0.090 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2013 | 384 | 0.090 |
Why?
|
| Mice, Inbred NOD | 1 | 2010 | 51 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2010 | 31 | 0.080 |
Why?
|
| Male | 6 | 2025 | 23409 | 0.080 |
Why?
|
| Neoplasm Transplantation | 1 | 2010 | 129 | 0.080 |
Why?
|
| Bone Marrow Cells | 1 | 2010 | 79 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2009 | 220 | 0.080 |
Why?
|
| Blotting, Western | 2 | 2009 | 883 | 0.080 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 2009 | 1 | 0.080 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 2009 | 1 | 0.080 |
Why?
|
| Myelopoiesis | 1 | 2009 | 2 | 0.080 |
Why?
|
| Tandem Repeat Sequences | 1 | 2009 | 10 | 0.080 |
Why?
|
| Leukemia, Myeloid | 1 | 2009 | 7 | 0.080 |
Why?
|
| Transfection | 1 | 2010 | 532 | 0.080 |
Why?
|
| Mice, Nude | 1 | 2010 | 408 | 0.070 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2009 | 38 | 0.070 |
Why?
|
| Interleukin-7 | 1 | 2008 | 8 | 0.070 |
Why?
|
| Cattle | 1 | 2010 | 498 | 0.070 |
Why?
|
| Stromal Cells | 1 | 2008 | 55 | 0.070 |
Why?
|
| Down-Regulation | 1 | 2010 | 456 | 0.070 |
Why?
|
| Luciferases | 1 | 2008 | 71 | 0.070 |
Why?
|
| Coculture Techniques | 1 | 2008 | 109 | 0.070 |
Why?
|
| Genes, Reporter | 1 | 2008 | 148 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2014 | 968 | 0.070 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2008 | 98 | 0.070 |
Why?
|
| Up-Regulation | 1 | 2010 | 536 | 0.070 |
Why?
|
| STAT3 Transcription Factor | 1 | 2008 | 102 | 0.070 |
Why?
|
| Biphenyl Compounds | 1 | 2007 | 53 | 0.070 |
Why?
|
| Inflammation Mediators | 1 | 2008 | 140 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 458 | 0.060 |
Why?
|
| Nuclear Proteins | 1 | 2009 | 333 | 0.060 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2007 | 46 | 0.060 |
Why?
|
| Amides | 1 | 2007 | 71 | 0.060 |
Why?
|
| Monocytes | 1 | 2009 | 277 | 0.060 |
Why?
|
| Leukocyte Elastase | 1 | 2025 | 12 | 0.060 |
Why?
|
| Glycine | 1 | 2025 | 47 | 0.060 |
Why?
|
| Peroxidase | 1 | 2025 | 57 | 0.060 |
Why?
|
| Cytokines | 1 | 2008 | 678 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2025 | 91 | 0.050 |
Why?
|
| Liposomes | 1 | 2025 | 132 | 0.050 |
Why?
|
| Mutation | 1 | 2009 | 1177 | 0.050 |
Why?
|
| Polymers | 1 | 2025 | 155 | 0.050 |
Why?
|
| Lipopolysaccharides | 1 | 2025 | 239 | 0.050 |
Why?
|
| Indoles | 1 | 2025 | 187 | 0.050 |
Why?
|
| Middle Aged | 4 | 2013 | 12222 | 0.050 |
Why?
|
| Extracellular Matrix | 1 | 2022 | 131 | 0.040 |
Why?
|
| Myocytes, Cardiac | 1 | 2022 | 183 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2009 | 116 | 0.040 |
Why?
|
| Prognosis | 2 | 2009 | 861 | 0.030 |
Why?
|
| STAT Transcription Factors | 1 | 2013 | 13 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2013 | 35 | 0.030 |
Why?
|
| Oncogene Protein v-akt | 1 | 2013 | 20 | 0.030 |
Why?
|
| Aged | 3 | 2013 | 8214 | 0.030 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2013 | 21 | 0.030 |
Why?
|
| I-kappa B Kinase | 1 | 2013 | 51 | 0.020 |
Why?
|
| Receptors, CCR2 | 1 | 2012 | 28 | 0.020 |
Why?
|
| Myeloid Cells | 1 | 2012 | 31 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2012 | 95 | 0.020 |
Why?
|
| Cisplatin | 1 | 2012 | 98 | 0.020 |
Why?
|
| Cell Death | 1 | 2012 | 278 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2012 | 508 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2009 | 8 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2009 | 14 | 0.020 |
Why?
|
| Adult | 3 | 2013 | 13872 | 0.020 |
Why?
|
| Korea | 1 | 2009 | 37 | 0.020 |
Why?
|
| Introns | 1 | 2009 | 79 | 0.020 |
Why?
|
| Exons | 1 | 2009 | 92 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 310 | 0.020 |
Why?
|
| Survival Rate | 1 | 2009 | 355 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 652 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2009 | 165 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2009 | 423 | 0.020 |
Why?
|
| Macrophages | 1 | 2012 | 529 | 0.020 |
Why?
|
| Adolescent | 2 | 2009 | 6081 | 0.020 |
Why?
|
| HL-60 Cells | 1 | 2007 | 33 | 0.020 |
Why?
|
| Disease Progression | 1 | 2009 | 667 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2013 | 2853 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2007 | 161 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2009 | 704 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2007 | 346 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2007 | 241 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2009 | 1271 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2009 | 2544 | 0.010 |
Why?
|
| Young Adult | 1 | 2009 | 5080 | 0.010 |
Why?
|